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Current evidence supports the central role of neuropeptides in the molecular mechanisms underlying dental pain. In particular,
substance P, a neuropeptide produced in neuron cell bodies localised in dorsal root and trigeminal ganglia, contributes to the
transmission andmaintenance of noxious stimuli and inflammatory processes. The major role of substance P in the onset of dental
pain and inflammation is increasingly being recognised. Well-grounded experimental and clinical observations have documented
an increase in substance P concentration in patients aﬀected by caries, pulpitis, or granulomas and in those undergoing standard
orthodontic or orthodontic/dental care procedures. This paper focuses on the role of substance P in the induction andmaintenance
of inflammation and dental pain, in order to define future lines of research for the evaluation of therapeutic strategies aimed at
modulating the complex eﬀects of this mediator in oral tissues.
1. Introduction
Pain is a widely accepted consequence of oral pathological
conditions and orthodontic procedures and represents one
of the major concerns for both patients and dentists [1]. It is
common known that the perception of dental pain is due, at
least in part, to an inflammatory reaction that involves dif-
ferent molecular mechanisms. Peripheral pain mechanisms
associated with odontogenic painful conditions are overall
similar to the mechanisms observed in all other body parts.
These similarities include the type of sensory neurons in-
volved as well as the diﬀerent molecules that play a role in
these processes (e.g., receptors, channels, transmitters, and
intracellular signalling eﬀectors responsible for the transduc-
tion, modulation, and propagation of peripheral stimuli) [2–
5]. The pain signal is conducted via thin fibers containing un-
myelinated C-fibers and myelinated A-δ fibers of primary
sensory neurons to secondary order neurons in the spinal
cord and finally to the cortex via a relay in the thalamus [3].
Peripheral terminal of nociceptors is environmental de-
tectors that are biochemically specialized by the expression
and localization of various receptors and ion channel which
confer to these cells the ability to detect noxious chemical,
thermal, and mechanical stimuli [3, 4].
A broad range of inflammatory mediators is produced by
diﬀerent cell types in response to tissue injury, and these me-
diators play diﬀerent roles in the modulation of pain sen-
sation [3]. The released inflammatory mediators act on the
specific receptors expressed in nociceptive sensory neuron
and result in the production of second messengers and the
downstream activation of protein kinase and phospholipases.
The second messengers regulate the activity of the many re-
ceptors and ion channels, leading to peripheral sensitization.
The ion channels open in response to noxious stimuli initi-
ating and propagating action potentials in the sensory neu-
rons [4]. Neuropeptides are now considered major determi-
nants of the inflammatory process in peripheral tissues, a
phenomenon also known as neurogenic inflammation [6].
Mounting evidence is also supporting the role of neuropep-
tides in the molecular mechanisms underlying dental pain
[7].
Substance P (SP) is a neuropeptide produced in a subset
of capsaicin sensitive sensory peripheral neuron cell bodies
localised in dorsal root and trigeminal ganglia, which plays
a pivotal role in the transmission of noxious stimuli in the
spinal cord [8]. Moreover, the stimulation of capsaicin-sen-
sitive sensory peripheral terminal of the neurons results in
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the peripheral release of several neuropeptides, including SP
[9, 10].
This brief work focuses on the role of SP in the induction
and maintenance of inflammation and dental pain as well as
possible future lines of research.We have to remark that other
neuropeptides beside SP are present in the same capsaicin
sensitive sensory neurons, with either proinflammatory, such
as calcitonin gene-related peptide (cGRP) and neurokinin A-
B, or antinflammatory activity such as galanin and soma-
tostatin [3–8]. However SP can be considered the more rep-
resentative peptide involved in neurogenic inflammation and
it is the most studied in dental physiology and pathology. Key
articles were identified by a targeted MEDLINE search using
appropriate keywords (e.g., substance P AND dental pain),
which was then manually refined by browsing the reference
lists of retrieved articles and by adding other relevant papers
according to the authors’ knowledge of the field.
2. Structure and Mechanisms of SP
SP is an s undecapeptide (H-Arg1-Pro2-Lys3-Pro4-Gln5-
Gln6-Phe7-Phe8-Gly9-Leu10-Met11-NH2) and belongs to
the same neuropeptide family as neurokinin (NK) A and
NK B [9, 11], all of which share the same carboxyl terminal
sequence, Phe-X-Gly-Leu-Met-NH2. SP is encoded by the
preprotachykinin-A gene in the perikaryon of primary aﬀer-
ent neurons in the dorsal root and trigeminal ganglia and
then is transported to both central and peripheral processes
of these elements [9, 11]. Interestingly, most (around 80%) of
the SP synthesised in dorsal root ganglia is exported towards
the terminal regions of their peripheral branches rather
than centrally [9–11]. A number of enzymes are involved in
the metabolism of substance P, due to their specific cellular
localization it is probably Neutral endopeptidase and angi-
otensin converting enzymes (EP and/or ACE) which aremost
commonly involved in the cleavage of substance P within the
periphery [11].
It is widely accepted that several factors can activate and/
or sensitise nociceptors at the site of tissue injury [8, 12] and
induce neuropeptide release in the periphery. Capsaicin,
heat, and protons activate vanilloid receptor 1 (VR1), which
is localized on small diameter sensory fibers resulting in
opening of a cation channel, increasing calcium entry
through this channel and through voltage-gated calcium
channels activated by sodium–induced depolarization. These
eﬀects increase SP release from sensory neurons. Bradikinin
binds to B2 receptors on sensory neurons and this results in
the stimulation of phospholipase C pathway with the acti-
vation of the protein kinase C (PKC) cascade that has been
demonstrated to stimulate SP secretion from sensory end-
ings. Other compounds do not directly excite sensory neu-
rons but sensitize them, since they lower the threshold for
firing. Prostaglandins, produced in inflamed tissue, bind to
their receptor on sensory fibers and lower the firing thresh-
olds of neurons throughout cAMP and protein kinase A. As a
consequence they also enhance SP release in response to cap-
saicin, bradikinin, and other stimuli. Finally other mediators
such as NGF, that binds to the high aﬃnity TrkA receptors
forming an NGf/TrkA complex that is internalized and trans-
ported to the neuron cell body, can sensitize the nociceptor
[6].
The biological eﬀects of released SP are induced follow-
ing its binding to specific G protein-coupled NK receptors
[11, 13]. There are three types of tachykinin receptors, NK1,
NK2, and NK3 exhibiting preferences for substance P, neu-
rokinin A, and neurokinin B, respectively, [11, 13]. However,
endogenous tachykinins are not highly selective for any given
receptor, and all can act on all three receptors under certain
conditions such as receptor availability or at high peptide
concentrations.Substance P primarily acts on NK1 receptors
and simulation of the NK1 receptor induces several second
messengers systems, such as phospholipase C intracellular
inositol 1,4,5-trisphophate (IP3) turnover with subsequent
elevation of intracellular calcium [11].
These receptors are present in high concentrations in
dental tissues [14, 15].
Moreover SP has been shown to activate ERK 2 and P38
mitogen-activated protein and to increase the production of
prostaglandin E2 and the expression of COX2 [16, 17].
The interaction of SP with its receptors directly induces
vasodilatation with increased blood vessel permeability and
allows plasma extravasation and mastocyte degranulation.
The mastocyte granules release histamine, which in turn fur-
ther amplifies vascular processes and activates nociceptors
[18]. Lymphocytes, granulocytes, and macrophages have
receptors for SP and these cells can be stimulated to produce
cytokines. Macrophages stimulated by SP produce the in-
flammatory mediators PGE2, thromboxane, as well as the
proinflammatory cytokines IL-1, IL-6, and TNF [11]. All
these molecular events ultimately sustain the synthesis and
release of new SP, therefore perpetrating the vicious circle
(Figure 1). Moreover, these mechanisms do not involve only
fibers at the site of tissue damage but are extended also to
surrounding undamaged tissues, where they cause secondary
hyperalgesia.
On this basis, SP can be considered a major mediator of
neurogenic inflammation and associated hyperalgesia and
represents a promising target for therapies aimed at control-
ling pain and minimising deleterious consequences of tissue
injury.
3. Dental Pulp Innervation and SP
The tooth pulp is a soft connective tissue that is densely in-
nervated and highly vascularised. It is enclosed by rigid min-
eralised dentin, which strongly limits the ability of the tissue
to increase in volume during inflammation and decreases the
level of immune defence [2]. Nerve fibers in the pulp include
aﬀerent (sensory) fibers originating from the trigeminal
ganglia and sympathetic fibers originating from the cervical
sympathetic ganglia. Parasympathetic innervation is also
present [7].
The number of trigeminal sensory fibers in dental pulp is
very high, and several types of sensory fibers are present in
this tissue; therefore, the stimulation of pulpal nerves results
mainly in pain sensations [2, 19, 20]. For instance, one single
human premolar contains 2300 axons at the apex, 87% of
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Figure 1: The role of substance P in neurogenic inflammation.
which are unmyelinated [21]. Recent findings indicate that
the regulation of innervation density is a dynamic process,
and the number of nerve fibers can increase in the presence
of caries or following orthodontal procedures [2].
SP is abundantly contained in the fibers that innervate
the dental pulp and dentin [7]. The production and release
of this molecule are highly increased upon noxious, thermal,
mechanical, and chemical stimulation of the dental pulp as
well as in periodontal ligament [7, 19, 22–24]. The amount of
SP released by each sensory fiber is further increased during
inflammatory processes, which sustains the vicious circle
that underlies inflammation [23, 25]. A number of studies
have measured SP concentrations in the human dental pulp,
reporting an increase up to 100-fold in inflamed teeth and up
to 1000-fold in irreversible pulpitis [25, 26].
4. SP and Its Receptors in Dental Pulp
SP exerts several eﬀects in dental pulp (Table 1) [7]. A few
studies have characterized the presence of NK receptors in
rodent and human teeth [27, 28]. Animal studies identified
the expression pattern of the tachykinin receptors NK1, NK2,
and NK3 in diﬀerent types of hard tissue cells, epithelial
cells, fibroblasts, endothelium, and blood vessel walls in teeth
and supporting oral tissues. NK1 and NK2 receptors have
been reported in odontoblast as well as in enamel forming
cells (ameloblasts). As expected NK1 receptor is abundantly
present on capillaries and smaller blood vessels, and both
NK1 and NK2 receptors are densely distributed on the
capillary plexus subjacent to dentin [27].
A pronounced density of NK2 receptor has been detected
in gingival andMalassez epithelium. NK1 and NK2 receptors
were also shown on fibroblasts in the periodontal ligament
and in the pulp [27]. Substance P receptors have been
reported also in human pulp tissue, although the methods
used for their evaluation, radioreceptor assay, did not allow
Table 1: Key eﬀects of substance P in dental pulp.
Healthy tissues
Maintenance of tissue homeostasis [6, 27, 28]
Inflamed tissues
Vasodilatatory response [6, 7]
Histamine release [29]
Increase in blood flow [29]
Increase in vascular permeability [29]
Increase in blood pressure [29]
Synthesis of proinflammatory cytokines [30, 31]
Chemotaxis of inflammatory cells [30]
Sensitisation of nociceptors [7]
to measure which type of receptor (NK1, NK,2 or NK3) was
primarily present [28].
Sensory fibers terminate near blood vessels, and SP re-
ceptors are present in high concentrations in this tissue
[27, 28]. In healthy tissues, basal SP release plays a key role
in the maintenance of tissue homeostasis; on the other hand,
massive release of this molecule due to external stimuli in-
duces a vasodilator response followed by a long-lasting in-
crease in blood flow [7]. The increased production and re-
lease of SP contributes to the initiation and propagation of
the inflammatory process.
SP interacts with mast cells and induces the release of
histamine, therefore causing elevated vascular permeability
and increased blood pressure [29]. Moreover, lymphocytes,
granulocytes, and macrophages contain receptors for SP,
and these cells can be stimulated by SP to produce proin-
flammatory mediators and cytokines [30, 31]. SP also acts
as a potent chemotactic agent, which recruits further inflam-
matory cells in the pulp tissue [30]. The large number of
inflammatory and nociceptive mediators dramatically sen-
sitises the nociceptors, stimulates them to release more SP
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Table 2: Conditions and dental care or orthodontic procedures
associated with increased substance P release.
Condition
Caries [25]
Pulpitis [26]
Granuloma [32]
Procedures
Cavity preparation [33]
Tooth movement [34, 35]
Tooth bleaching [22]
both in the spinal cord and in the dental pulp, and further
increases pain sensitivity [7].
5. SP in Pathological Dental Conditions
Almost all pathological conditions that aﬀect oral tissues, as
well as orthodontic or dental care procedures, increase the
production and release of SP (Table 2).
The results of an ex vivo study have shown that SP ex-
pression is significantly greater in grossly carious painful mo-
lars than in grossly carious asymptomatic molars [25]. Mean
extracellular levels of SP were >8-fold greater in teeth diag-
nosed with irreversible pulpitis than in dental pulp diagnosed
as normal, as reported by a study in 21 patients, and an in-
crease in SP concentration was observed in granuloma tis-
sues, when compared with healthy controls [26, 32]. Interest-
ingly, also Substance P receptor expression in human pulp
tissue is significantly increased during inflammatory phe-
nomena such as acute irreversible pulpitis [28].
Considering that SP exerts its biological activity mainly
via the high aﬃnity NK1 receptors but that at higher con-
centrations the peptide can activate also NK2 and NK3 re-
ceptors, it can be speculated that while in physiological con-
dition NK1 is the most involved receptors, in pathological
conditions, due to the higher SP concentrations, also NK1
and NK2 become involved.
It has been suggested that SP innervation and SP-related
neurogenic inflammation could play a role in several ortho-
dontic procedures.
Deep cavity preparation (<1mm remaining dentine
thickness) for orthodontic reasons was associated with a sig-
nificant increase in the concentration of SP in pulp tissue,
compared with controls [33]. It is well known that root ca-
nal preparation generates an inflammatory process in the
periapical tissues, which could explain the posttreatment
pain events after root canal therapy (such as symptomatic
apical periodontitis). Interestingly, it was demonstrated that
SP is released in the periodontal ligaments as a result of the
application of diﬀerent canal preparation techniques, al-
though the amount of released SP diﬀers among procedures.
SP increase could generate an inflammatory process in the
periapical tissues [34, 35].
A recent study has also shown that dentin bonding agents
used in restorative dentistry can moderately increase SP re-
lease in the dental pulp. This eﬀect is likely to be a result
of reactive oxygen species that are formed, which have the
ability to diﬀuse through dentinal tubules, constituting a bio-
logical risk to the pulp. Because cavity preparation and the
use of dentine bonding agents cooccur very often, a final sig-
nificant alteration of SP concentrations is likely to occur, that
participates in neurogenic inflammation [36].
Similarly, an increase in SP expression and release was
observed in patients undergoing orthodontic tooth move-
ment, which was associated with enhanced synthesis of
proinflammatory cytokines [34, 37].
Interestingly the kinetic of SP release parallels the per-
ception of pain during orthodontic treatment, which sug-
gests that the perception of pain may be linked to the release
of SP [38–40].
Further studies have analyzed the impact of diﬀerent
bracket systems on SP concentrations, with the aim of reduc-
ing the inflammation and pain resulting from these proce-
dures [34].
A high level of SP expression has also been reported fol-
lowing procedures with a low impact on tooth physiology,
such as light- and laser-activated tooth bleaching [22].
Although it is not possible to reach a conclusion about
the biological role of SP release during orthodontic move-
ment, it can be suggested that its release as a consequence
of the stimulation of peripheral nerve terminals by means of
orthodontic forces may trigger a biochemical cascade which
comprises the activation of various types of periodontal
ligament cells that could eventually favour inflammatory
processes.
6. Conclusions and Future Directions
Overall, evidence collected so far strongly supports the major
role of SP in the development and maintenance of dental
pain and inflammation. An increase in the expression and
release of this molecule has been demonstrated following
several pathological conditions and common dental proce-
dures. Although physiological levels of SP are needed in order
to guarantee correct blood flow in the dental pulp that can
help tissue healing, from the available literature it clearly ap-
pears that high levels of the neuropeptide are associated
with pain and persistent inflammation. Clinicians should be
aware that most orthodontic procedures have an impact on
the pulpodentine complex, which could generate several
neurogenic and vascular reactions, including the release of
SP. Although the number of reports in the literatures is only
few, there is emerging the evidence that not all orthodontic
procedures have a similar impact on SP release [34, 35, 37]. It
should therefore become possible to choose approaches with
limited eﬀects on SP release.
A second approach to blunt the consequences of SP
would be to target with appropriate pharmacological treat-
ment either SP release or SP binding to its receptors present
in the pulp. It has been documented that the injection of lo-
cal anaesthetics results in the attenuation of SP release [19,
41]. This strategy, although potentially useful for limiting
the increase in SP concentration, cannot be applied for all
conditions and becomes almost useless for the treatment of
chronic disease. The use of modulators or blockers of SP
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receptors has been recently suggested [6], but further ev-
idence is required to fully characterise the benefit/risk ra-
tio of these molecules. Although many studies show the an-
tinociceptive eﬀects of NK1 receptor antagonists, several
clinical trials have failed to demonstrate the analgesic eﬃcacy
of these compounds in humans [42, 43], though they have
been successful in the treatment of other diverse conditions,
including depression, chemotherapy-induced emesis, and
inflammatory bowel disease [44]. Future studies are neces-
sary to evaluate the usefulness of NK1 receptor antagonists
to treat dental pain.
To our knowledge, the eﬀects on SP expression and re-
lease of common analgesic treatments used to control pain
after dental procedures have not been intensely investigated
to date. For instance, nimesulide reduces the concentration
of pain mediators, including SP, in patients with knee oste-
oarthritis [45], but the eﬀects of this agent in dental pain
have not been assessed. However, the same pharmacologic
eﬀects in dental tissues cannot be excluded and can be
extended to other nonsteroidal anti-inflammatory drugs
(NSAIDs), although ad hoc studies are required to confirm or
discard these hypotheses. Therefore, we believe that careful,
evidence-based evaluation of the eﬀects of single NSAIDs on
the modulation of SP expression, neurogenic inflammation,
and sensory neuron excitability in the dental pulp should be
pursued in the future.
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